ACS Medicinal Chemistry LettersPharmacology & ToxicologyPeer-reviewed journal article
Virtual Screening-Guided Discovery of Small Molecule CHI3L1 Inhibitors with Functional Activity in Glioblastoma Spheroids
Baljit KauriD, Katrin DenzingeriD, Longfei ZhangiD, Nelson García-Vázquez, Gerhard WolberiD, Moustafa Tarek GabriD
Abstract
Chitinase-3-like protein 1 (CHI3L1), a glycoprotein implicated in inflammation, fibrosis, and cancer, has emerged as a potential therapeutic target for glioblastoma (GBM). CHI3L1 contributes to tumor progression and immune evasion by promoting STAT3 signaling and mesenchymal transition. To identify small molecule CHI3L1 inhibitors, a structure-based 3D pharmacophore model was developed and applied to virtually screen over 4.4 million compounds from the Enamine collection. Following multi-tiered filtering, 35 candidates were selected for experimental evaluation. Binding validation via microscale thermophoresis (MST) confirmed dose-dependent CHI3L1 interactions for two compounds, 8 and 39, with dissociation constants (Kd) of 6.8 {micro}M and 22 {micro}M, respectively. These affinities were further supported by surface plasmon resonance (SPR), which yielded Kd values of 5.69 {micro}M for compound 8 and 17.09 {micro}M for compound 39. In 3D GBM spheroid models, compound 8 significantly reduced spheroid viability and attenuated phospho-STAT3 levels, consistent with CHI3L1 pathway disruption. These findings identify two promising scaffolds and support the utility of pharmacophore-guided virtual screening for discovering functionally active ligands targeting CHI3L1 in GBM. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=139 SRC="FIGDIR/small/667816v1_ufig1.gif" ALT="Figure 1"> View larger version (39K): org.highwire.dtl.DTLVardef@291464org.highwire.dtl.DTLVardef@f9d224org.highwire.dtl.DTLVardef@1535eeaorg.highwire.dtl.DTLVardef@7c596e_HPS_FORMAT_FIGEXP M_FIG Table of Contents artwork C_FIG
- organism: human
- assay: proteomics
- research focus: drug response / drug discovery
- approach: deep learning
- Citations
- 2
- FWCI
- 1.03
- Field percentile
- top 22%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- CHI3L1-Targeted Small Molecules as Glioblastoma Therapies: Virtual Screening-Based Discovery, Biophysical Validation, Pharmacokinetic Profiling, and Evaluation in Glioblastoma Spheroids
Hossam Nada, Longfei Zhang, … Moustafa Tarek Gabr·European Journal of Medicinal ChemistryPeer-reviewed·Jul 15, 2025
- Structure-Guided Discovery of CHI3L1 Inhibitors from Ultralarge Chemical Spaces for Glioblastoma Therapy
Baljit Kaur, François Sindt, … Moustafa Tarek Gabr·ACS OmegaPeer-reviewed·Dec 21, 2025
- Discovery of Small Molecule CHI3L1 Inhibitors by SPR-Based High-Throughput Screening
Longfei Zhang, Hossam Nada, Moustafa Tarek Gabr·Bioorganic & Medicinal Chemistry LettersPeer-reviewed·Nov 4, 2025
- Structural Optimization of CHI3L1 Inhibitors with Improved Pharmacokinetics and Functional Activity in 3D Glioblastoma Models
Baljit Kaur, Hossam Nada, Moustafa Tarek Gabr·Journal of Enzyme Inhibition and Medicinal ChemistryPeer-reviewed·May 11, 2026
- Resistance-Mutant Rescue Establishes On-Target CHI3L1 Inhibition by CHI-DEL, a Brain-Penetrant Small Molecule with In Vivo Efficacy in Glioblastoma
Saurabh Upadhyay, Longfei Zhang, … Moustafa Gabr·bioRxiv·Oct 24, 2026
- Stabilizing the CHI3L1-Gal3BP complex remodels the glioblastoma immune microenvironment and synergizes with PD-1 blockade
Saurabh Upadhyay, Longfei Zhang, … Moustafa Gabr·bioRxiv·Oct 27, 2026